Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Conserved HBV and HCV sequences useful for gene silencing
US9982263B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9982263-B2 |
| Application number | US-201514921510-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 23, 2015 |
| Priority date | Jun 12, 2003 |
| Publication date | May 29, 2018 |
| Grant date | May 29, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
First claim
Opening claim text (preview).
We claim: 1. A method for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising administering to said cell at least one double-stranded RNA effector molecule comprising a sequence targeted to at least 19 contiguous nucleotides within coordinates 2791-2811 of Genbank accession number V01460 (SEQ ID NO: 266). 2. The method of claim 1 , wherein the mammalian cell is a human cell.
Assignees
Inventors
Classifications
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Special therapeutic applications · CPC title
- C12N15/1131Primary
against viruses · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9982263B2 cover?
- Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
- Who is the assignee on this patent?
- Alnylam Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1131. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).